 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8384858687888990919293...100101» |
- || Enrollment closed, Trial primary completion date, IO biomarker, Metastases: Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=175, Active, not recruiting, Sponsor: VU University Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment change, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Mar 30, 2017
P1, N=225, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Sep 2017 N=300 --> 225
- |||||||||| Kisqali (ribociclib) / Novartis
New P3 trial, Combination therapy, Metastases: RIBECCA: Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 30, 2017
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Merional (menotropin) / IBSA Institute Biochemical SA, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
Trial primary completion date: AIPRICSI: Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (clinicaltrials.gov) - Mar 29, 2017
P4, N=20, Recruiting, Sponsor: Minia University
N=300 --> 225 Trial primary completion date: Jan 2017 --> Apr 2017
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Mar 27, 2017
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Trial primary completion date: Jan 2017 --> Apr 2017 N=160 --> 250 | Trial primary completion date: Dec 2016 --> Jul 2017
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 27, 2017
P3, N=660, Recruiting, Sponsor: Novartis Pharmaceuticals
N=160 --> 250 | Trial primary completion date: Dec 2016 --> Jul 2017 Active, not recruiting --> Recruiting
- |||| Kisqali (ribociclib) / Novartis
Trial primary completion date, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Mar 24, 2017
P3, N=3000, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial primary completion date: Nov 2020 --> Nov 2019
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2020 --> Nov 2019 Trial primary completion date: Dec 2017 --> Apr 2020
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date: Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=20, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2017 --> Apr 2020 Trial primary completion date: Nov 2016 --> Nov 2017
- || samotolisib (LY3023414) / Eli Lilly
Trial primary completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Mar 21, 2017
P1, N=130, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Jul 2017 --> Mar 2018
- | letrozole / Generic mfg.
Enrollment closed, Enrollment change, Trial initiation date: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment (clinicaltrials.gov) - Mar 21, 2017
P2/3, N=35, Active, not recruiting, Sponsor: Helsinki University Central Hospital
Trial primary completion date: Jul 2017 --> Mar 2018 Recruiting --> Active, not recruiting | N=50 --> 35 | Initiation date: Feb 2013 --> Oct 2013
- Ibrance (palbociclib) / Pfizer
Trial suspension, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Mar 20, 2017
P1, N=25, Suspended, Sponsor: Pfizer
Recruiting --> Active, not recruiting | N=50 --> 35 | Initiation date: Feb 2013 --> Oct 2013 Active, not recruiting --> Suspended
- Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Mar 14, 2017
P1, N=25, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Suspended Trial primary completion date: Aug 2017 --> Dec 2017
- | letrozole / Generic mfg., exemestane / Generic mfg.
Trial completion, Trial primary completion date, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Mar 14, 2017
P2, N=60, Completed, Sponsor: Xichun Hu
Trial primary completion date: Aug 2017 --> Dec 2017 Trial primary completion date: Jun 2017 --> Jul 2014 | Active, not recruiting --> Completed
- || Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Mar 8, 2017
P2, N=160, Active, not recruiting, Sponsor: Japan Breast Cancer Research Group
Trial primary completion date: Jun 2017 --> Jul 2014 | Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2018
- ||| Piqray (alpelisib) / Novartis, buparlisib (AN2025) / Novartis, Adlai Nortye
Enrollment closed: Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women (clinicaltrials.gov) - Mar 7, 2017
P2, N=338, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Active, not recruiting
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2017
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- ||| taselisib (GDC-0032) / Roche
Enrollment closed: A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) (clinicaltrials.gov) - Feb 27, 2017
P2, N=330, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Feb 24, 2017
P1, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2019 --> May 2019
- || gedatolisib (PF-05212384) / Celcuity
Trial initiation date, Trial primary completion date, Combination therapy, Metastases: B2151009: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 24, 2017
P1b, N=120, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2019 --> May 2019 Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: May 2019 --> Sep 2019
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 23, 2017
P2, N=42, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2015 --> Jun 2016 | Trial primary completion date: May 2019 --> Sep 2019 Trial primary completion date: Apr 2017 --> Apr 2018
- | paclitaxel / Generic mfg.
New P2 trial: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Feb 23, 2017
P2, N=60, Not yet recruiting, Sponsor: University of Chicago
- || Piqray (alpelisib) / Novartis
Enrollment closed, Trial primary completion date, Metastases: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 17, 2017
P1, N=52, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Apr 2017 --> Apr 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> May 2018
- ||||| Piqray (alpelisib) / Novartis
New P2 trial, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Feb 16, 2017
P2, N=160, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||| Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Enrollment open: Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) (clinicaltrials.gov) - Feb 16, 2017
P, N=60, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> May 2018 Not yet recruiting --> Recruiting
- Ibrance (palbociclib) / Pfizer
Enrollment closed: Palbociclib and FES PET (clinicaltrials.gov) - Feb 15, 2017
P2, N=15, Active, not recruiting, Sponsor: University Medical Center Groningen
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
New P1/2 trial, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Feb 15, 2017
P1/2, N=40, Not yet recruiting, Sponsor: University of Colorado, Denver
- |||||||||| Kisqali (ribociclib) / Novartis
New P3 trial: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib (clinicaltrials.gov) - Feb 10, 2017
P3, N=140, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy, Metastases: Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms (clinicaltrials.gov) - Feb 6, 2017
P2, N=108, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Recruiting --> Active, not recruiting Terminated --> Completed
- |||| Zarnestra (tipifarnib) / Kura Oncology
Trial completion, Metastases: Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - Feb 6, 2017
P2, N=121, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Terminated --> Completed Active, not recruiting --> Completed
- || gedatolisib (PF-05212384) / Celcuity
Trial initiation date, Combination therapy, Metastases: B2151009: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 31, 2017
P1b, N=120, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Initiation date: Jun 2016 --> Dec 2015
- letrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date, Metastases: Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=60, Active, not recruiting, Sponsor: Xichun Hu
Initiation date: Jun 2016 --> Dec 2015 Trial primary completion date: Dec 2016 --> Jun 2017
- letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov) - Jan 26, 2017
P1, N=42, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Jul 2018 --> Jul 2019
- Trial primary completion date, Metastases: LEO: Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=137, Recruiting, Sponsor: Asan Medical Center
Trial primary completion date: Jul 2018 --> Jul 2019 Trial primary completion date: Jul 2016 --> Dec 2017
- | letrozole / Generic mfg.
Trial completion, Trial primary completion date: Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion (clinicaltrials.gov) - Jan 26, 2017
P2/3, N=400, Completed, Sponsor: Ain Shams University
Trial primary completion date: Jul 2016 --> Dec 2017 Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2016
- | Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche
Trial initiation date, Trial primary completion date: PALTAN: Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (clinicaltrials.gov) - Jan 26, 2017
P2, N=48, Not yet recruiting, Sponsor: Washington University School of Medicine
Recruiting --> Completed | Trial primary completion date: Aug 2016 --> Dec 2016 Initiation date: Nov 2016 --> Feb 2017 | Trial primary completion date: Apr 2019 --> Jul 2019
- || letrozole / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Metastases: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) - Jan 24, 2017
P1/2, N=54, Active, not recruiting, Sponsor: Rutgers, The State University of New Jersey
Initiation date: Nov 2016 --> Feb 2017 | Trial primary completion date: Apr 2019 --> Jul 2019 Trial primary completion date: May 2017 --> May 2018
- megestrol / Generic mfg.
New P2 trial, Metastases: MEGA: A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Jan 19, 2017
P2, N=20, Not yet recruiting, Sponsor: Instituto Nacional de Cancer, Brazil
- letrozole / Generic mfg.
Enrollment closed, Trial primary completion date: PLUM: Pilot of Letrozole for Uterine Myomas (clinicaltrials.gov) - Jan 17, 2017
P4, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: May 2017 --> May 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2017
- Trial primary completion date: Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients (clinicaltrials.gov) - Jan 14, 2017
P3, N=104, Recruiting, Sponsor: Dharmais National Cancer Center Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- hydrocortisone / Generic mfg., flutamide / Generic mfg.
Trial completion, Trial completion date, Combination therapy: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jan 13, 2017
P1, N=62, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Dec 2016 --> Mar 2017 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jan 2017
- || Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Jan 11, 2017
P1, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Jan 2017 Trial primary completion date: Dec 2018 --> Dec 2019
- |||| Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 10, 2017
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Jun 2017 --> Nov 2017
- Merional (menotropin) / IBSA Institute Biochemical SA, Choriomon (human choriomon gonadotropin (hCG)) / IBSA Institute Biochemical SA
Trial primary completion date: AIPRICSI: Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI (clinicaltrials.gov) - Jan 6, 2017
P4, N=20, Recruiting, Sponsor: Minia University
Trial primary completion date: Jun 2017 --> Nov 2017 Trial primary completion date: Oct 2016 --> Jan 2017
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
New P3 trial: TALES: Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial (clinicaltrials.gov) - Jan 5, 2017
P3, N=144, Recruiting, Sponsor: University of California, San Francisco
- |||||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: CompLEEment-1: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC (clinicaltrials.gov) - Jan 4, 2017
P3, N=3000, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- || letrozole / Generic mfg.
New P3 trial: Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome (clinicaltrials.gov) - Jan 3, 2017
P3, N=150, Recruiting, Sponsor: Assiut University
- Ibrance (palbociclib) / Pfizer
New P2 trial, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Jan 3, 2017
P2, N=35, Not yet recruiting, Sponsor: Washington University School of Medicine
- ||||| Kisqali (ribociclib) / Novartis
New P2 trial, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jan 3, 2017
P2, N=76, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- letrozole / Generic mfg., nintedanib / Generic mfg.
Trial primary completion date: Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics (clinicaltrials.gov) - Dec 30, 2016
P1, N=22, Recruiting, Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Jul 2017